Pantherics Inc. is leading the discovery of small-molecule drugs that modulate peripheral GABAA receptors (GABAAR) for the treatment of inflammatory diseases of smooth muscle. This presentation will share how the company’s platform technology and new therapeutic category offer a fundamentally novel and safe mechanism of action for inflammatory disease treatment, addressing unmet therapeutic needs in pulmonary, gastrointestinal and urinary tract disorders.